2012-2018年北京市抗结核药物使用趋势分析  

Trend analysis on antitubercular agents in Beijing from 2012 to 2018

作　　者：孔雨薇 王立贵[2] 杜昕颖[2] 宋宏彬[2] 林叶青 赵康涛 郑溪水[2] KONG Yu-wei;WANG Li-gui;DU Xin-ying;SONG Hong-bin;LIN Ye-qing;ZHAO Kang-tao;ZHENG Xi-shui(The Joint Logistic Support Unit No.900 Hospital of Bengbu Medical College Teaching Hospital,Fuzhou,Fujian 350025,China)

机构地区：[1]蚌埠医学院教学医院联勤保障部队第九〇〇医院感染控制科,福建福州350025 [2]中国人民解放军疾病控制预防中心,北京100071 [3]联勤保障部队第九〇〇医院,福建福州350025 [4]福建省疾病控制预防中心,福建福州350025

出　　处：《中华医院感染学杂志》2020年第8期1228-1233,共6页Chinese Journal of Nosocomiology

基　　金：国家重大传染病专项基金资助项目(2017ZX10303401)。

摘　　要：目的分析北京市2012-2018年抗结核药物的使用情况与变化趋势,为北京市进一步规范及修改结核药物的使用策略提供数据参考。方法对2012-2018年北京市46家医院J04A类抗结核药物的销售金额、用药频度(Defined daily doses,DDDs)、药品限定日费用(Defined daily cost,DDC)等指标进行统计分析与评价。采用SPSS 22.0线性回归分析,判断变化趋势。结果 2012-2018年抗结核药销售金额逐年上升,而销售量在2016年到达高峰后缓慢下降;2012年和2018年相比抗结核的药物种类构成变动不大,各类药物销售金额构成变化较大;抗结核药物以一线、口服为主,二线、注射为辅,且二线用药的销售金额、DDDs和注射用药的销售金额有上升的趋势(P均<0.05);抗生素销售单价以注射类经济负担最重,且2018年较2012年,大部分种类药物都有不同程度的价格增长。结论抗结核药物的DDDs在2012-2018年间保持平稳,但大部分种类抗结核药物的DDC均出现上升趋势,患者经济负担增大,且抗结核药物使用存在用药集中的现象,带来的耐药风险不容忽视。OBJECTIVE To analyze antitubercular agents use and the trend of change in Beijing by the retrospective research on the antitubercular agents data in 46 hospitals in Beijing from 2012 to 2018, in order to provide policy recommendations for further modification and standardization and of antitubercular agents use strategy. METHODS The sales amount, defined daily doses(DDDs) and defined daily cost(DDC) of antitubercular drug used in 46 hospitals in Beijing were obtained and analyzed. The trend in antitubercular agent use was analyzed by using SPSS 22.0 for the linear regression. RESULTS The sales amount of antitubercular agents increased year by year from 2012 to 2018, and the total sales declined slowly after experiencing a small peak in 2016. Compared between 2012 and 2018, the composition of antitubercular agents types was almost the same, and the composition of sales amount of various drugs changed greatly. Oral and first-line antitubercular agents were the main treatment, supplemented with the second-line antitubercular agents and injection. The sales amount of second-line drugs, DDDs and sales amount of injection drugs had an upward trend(P<0.05). The economic burden of the retail price of antibiotic sales was the highest in injection. Compared with 2012, the retail price of most kinds of drugs had increased in 2018. CONCLUSION The DDDs of antitubercular agents remained stable during 2012 to 2018, but the defined daily cost(DDC) of most kinds of antitubercular agents showed an upward trend. The economic burden of patients increased. The use of anti-tuberculosis drugs was selected, which increased the risk of drug resistance that should not be ignored.

关 键 词：抗结核病药物 医院 趋势分析 

分 类 号：R978.3[医药卫生—药品]